Cancer Research

#Cancer research #Drug development #Drug discovery #Genes

New study able to detect BRCA1 breast cells before they turn cancerous

The earliest changes that occur in seemingly healthy breast tissue before tumours appear may have been found by researchers, suggests a new study published in Nature Communications. The study in mice, funded by Cancer Research UK, showed that before becoming cancerous, breast cells with the BRCA1 gene mutation undergo changes similar… Read More

#Cancer Research #News

#Biologics / Biotechnology #Cancer immunotherapy #Cancer research #Drug development

Pathios Therapeutics boosted with Innovate UK funding

Pathios, a biotech company focused on the development of first-in-class therapies for cancer, announced that it has been awarded £350K in the form of a Smart Grant from Innovate UK. The UK government innovation agency’s money will accelerate Pathios’ cancer immunotherapy programme which targets the innate immune checkpoint, GPR65. Pathios… Read More

#Cancer Research #News

#Cancer research #Drug development #Therapeutics

Vivan Therapeutics joins global Repositive Cancer Model network

Repositive has announced that UK-based personalised therapeutics company Vivan Therapeutics will join its network of cancer model partners. Vivan Therapeutics is a personalised therapeutics company that engineers drosophila ‘avatar’ models for cancer research and development. Its technology engineers the genetic complexity of a cancer patient’s unique tumour network (up to… Read More

#Cancer Research #News

#Biotherapeutics #Cancer research #Clinical Trial Authorisation

Avacta announces Phase I Clinical Trial Authorisation (CTA) for AVA6000

Avacta, the developer of Affimer biotherapeutics and reagents, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin. In AVA6000, doxorubicin has been modified with Avacta’s pre|CISION… Read More

#Cancer Research #News

#Biologics #Cancer immunotherapy #Oncology

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal… Read More

#Cancer Research #News

#Biotherapeutics #Microbiome #Oncology #Pharmaceuticals

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Immuno-oncology #Oncology

UCL and AstraZeneca collaborate on immuno-oncology research

Researchers from UCL Division of Infection & Immunity will lead on two collaborative projects with AstraZeneca. The projects’ long-term aim is to contribute to the development of new cancer treatments. These research collaborations will investigate immune checkpoints which are key biochemical pathways that regulate our body’s immune responses. These are… Read More

#Cancer Research #Editor's Choice #News

#Immuno-oncology #Immunotherapy #Mouse models

Taconic Biosciences expands immuno-oncology animal model portfolio

Taconic Biosciences, global provider of drug discovery animal model solutions, has expanded its immuno-oncology portfolio. Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. Syngeneic tumour animal models play a critical role because they use standard inbred mice… Read More

#Cancer Research #News

#Immunotherapy #Oncology

Genetic changes in tumours could help predict if patients will respond to immunotherapy

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients. Immunotherapies have led to huge progress treating certain types… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Biologics / Biotechnology #Clinical trials #Oncology

The importance of partnership and innovation in oncology

Fostering synergies to accelerate innovation in oncology and make it attractive for partners has been the MATWIN motto for over a decade, writes CEO Lucia Robert, MATWIN who outlines the organisations’s work MATWIN is a French open-innovation platform dedicated to supporting innovation in oncology. For more than ten years, its… Read More

#Cancer Research #Exclusive Content #News

#Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models — inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain — are invaluable preclinical research tools that enable tumour studies in the context of a complete… Read More

#Cancer Research #News